Completed PHASE2 INTERVENTIONAL 3-arm NCT00298155

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer (TAPS)

Sponsor: AstraZeneca

Interventions goserelin with bicalutamide and dutasteride goserelin with bicalutamide and dutasteride and ketoconazole goserelin with dutasteride

Updated 11 times since 2017 Last updated: Jul 12, 2018 Started: Jul 31, 2006 Primary completion: Jun 30, 2010 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cancer and Prostate Neoplasms and is currently completed. AstraZeneca leads this study, which shows 11 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Aug 2018 — Sep 2018 [monthly]

Completed PHASE2
Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Jul 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2017 — Jul 2017 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
GlaxoSmithKline
University of Washington

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States